Published in Lancet on July 07, 2007
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 4.68
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis (2011) 2.84
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol (2009) 2.31
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother (2009) 1.69
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (2010) 1.49
Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother (2011) 1.49
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother (2010) 1.45
Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother (2008) 1.38
Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One (2012) 1.22
Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol (2012) 1.16
First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment. Antimicrob Agents Chemother (2014) 1.09
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother (2015) 1.06
Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. PLoS One (2013) 0.87
In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother (2012) 0.82
Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2014) 0.76
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 4.68
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet (2008) 4.44
Multiple-triazole-resistant aspergillosis. N Engl J Med (2007) 3.33
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis (2009) 3.03
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis (2004) 3.02
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis (2011) 2.84
In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 2.80
Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat (2009) 2.63
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother (2002) 2.36
Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. Pediatr Pulmonol (2011) 2.32
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol (2009) 2.31
Aspergillus PCR: one step closer to standardization. J Clin Microbiol (2010) 2.23
Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. Laryngoscope (2014) 2.21
Saffold virus, a human Theiler's-like cardiovirus, is ubiquitous and causes infection early in life. PLoS Pathog (2009) 2.15
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol (2006) 2.14
Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother (2003) 2.09
Therapeutic drug monitoring of voriconazole. Ther Drug Monit (2008) 2.09
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis (2013) 2.09
Respiratory infections in Eñepa Amerindians are related to malnutrition and Streptococcus pneumoniae carriage. J Infect (2013) 2.06
Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol (2006) 2.05
Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck (2011) 1.97
CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res (2010) 1.97
Azole-resistant central nervous system aspergillosis. Clin Infect Dis (2009) 1.94
Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis (2003) 1.91
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis (2007) 1.83
Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis (2006) 1.79
A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev Cell (2006) 1.77
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One (2010) 1.77
A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med (2013) 1.75
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis (2009) 1.73
Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One (2012) 1.71
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother (2009) 1.69
Interlaboratory evaluation of different extraction and real-time PCR methods for detection of Coxiella burnetii DNA in serum. J Clin Microbiol (2010) 1.65
Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. J Ethnopharmacol (2006) 1.64
Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother (2012) 1.62
Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis (2013) 1.59
Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol (2003) 1.59
A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-golgi transport. J Virol (2005) 1.59
Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol (2012) 1.55
Multidrug resistance in Aspergillus fumigatus. N Engl J Med (2002) 1.54
Effects of picornavirus 3A Proteins on Protein Transport and GBF1-dependent COP-I recruitment. J Virol (2006) 1.50
Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo. J Clin Microbiol (2002) 1.49
Genotypic diversity of Coxiella burnetii in the 2007-2010 Q fever outbreak episodes in The Netherlands. J Clin Microbiol (2011) 1.49
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (2010) 1.49
Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother (2011) 1.49
The mengovirus leader protein suppresses alpha/beta interferon production by inhibition of the iron/ferritin-mediated activation of NF-kappa B. J Virol (2002) 1.48
The mengovirus leader protein blocks interferon-alpha/beta gene transcription and inhibits activation of interferon regulatory factor 3. Cell Microbiol (2007) 1.47
Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell (2008) 1.46
Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol (2011) 1.45
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother (2010) 1.45
comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol (2005) 1.44
Patients with cervical cancer: why did screening not prevent these cases? Am J Obstet Gynecol (2011) 1.44
Sinonasal tumors: a clinicopathologic update of selected tumors. Eur Arch Otorhinolaryngol (2012) 1.43
Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis (2008) 1.43
Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol (2008) 1.43
Parental acceptance of Human Papillomavirus vaccines. Eur J Obstet Gynecol Reprod Biol (2007) 1.43
Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw (2006) 1.41
Structural and functional characterization of the coxsackievirus B3 CRE(2C): role of CRE(2C) in negative- and positive-strand RNA synthesis. J Gen Virol (2006) 1.39
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res (2007) 1.37
Identification of Paecilomyces variotii in clinical samples and settings. J Clin Microbiol (2010) 1.37
Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis (2005) 1.36
1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med (2006) 1.35
Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol (2005) 1.34
Aspergillus species intrinsically resistant to antifungal agents. Med Mycol (2010) 1.33
Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis (2004) 1.33
Advances and applications of oral cancer basic research. Oral Oncol (2011) 1.33
Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. Prostate (2010) 1.30
Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol (2010) 1.26
Molecular determinants of the interaction between coxsackievirus protein 3A and guanine nucleotide exchange factor GBF1. J Virol (2007) 1.25
The coxsackievirus 2B protein suppresses apoptotic host cell responses by manipulating intracellular Ca2+ homeostasis. J Biol Chem (2004) 1.23
Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One (2012) 1.22
Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis (2004) 1.22
Determinants for membrane association and permeabilization of the coxsackievirus 2B protein and the identification of the Golgi complex as the target organelle. J Biol Chem (2002) 1.22
Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health (2006) 1.22
Human papillomavirus infections in laryngeal cancer. Head Neck (2011) 1.22
Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck (2010) 1.20
Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol (2004) 1.19
Surgical margins in head and neck cancer: a contemporary review. Head Neck (2012) 1.19
Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck (2008) 1.18
Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol (2008) 1.17
Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol (2008) 1.17
In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol (2006) 1.16